Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex

Table 1

Demographic data of the studied patients.

Parameter		Avonex (𝑛=34)	CinnoVex (𝑛=43)	𝑃 value
Age, year (mean ± SD)		30.5 ± 8.9	32.3 ± 9.0
	<20, 𝑛 (%)	4 (11.8%)	0
	20–30, 𝑛 (%)	15 (44.1%)	20 (46.5%)	0.203
	30–40, 𝑛 (%)	11 (32.3%)	16 (37.2%)
	>40, 𝑛 (%)	4 (11.8%)	7 (16.3%)
Sex, female, 𝑛 (%)		31 (91.1%)	31 (72.0%)	0.036
Marital status, single, 𝑛 (%)		18 (52.9%)	18 (41.8%)	0.333
Age at disease onset, year (mean ± SD)		26.1 ± 9.0	29.4 ± 8.7	0.165
Family history of MS, 𝑛 (%)		2 (5.9%)	5 (11.6%)	0.384